Barclays Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $78

Benzinga Newsdesk www.benzinga.com Positive 61.4%

Neg 0% Neu 0% Pos 61.4%

Barclays analyst Etzer Darout initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Overweight rating and announces Price Target of $78.